FDA WARNING_LETTER - DeJong Family Dairy, LLC - April 08, 2026

The U.S. Food and Drug Administration (FDA) issued a formal warning letter to DeJong Family Dairy, LLC, following an inspection of its Dorchester, Wisconsin, facility on April 6 and 8, 2026. The inspection identified significant violations of the Federal Food, Drug, and Cosmetic Act regarding the improper administration of animal medications. Specifically, the dairy was found to be engaging in the unauthorized "extralabel" use of an intramammary infusion drug. Records indicated that multiple cows were treated with the medication in a manner that contradicted the manufacturer’s label instructions. Under federal law, using animal drugs in a way that deviates from the label is only permitted under the direct order of a licensed veterinarian within a valid professional relationship. Because the dairy administered these treatments without such an order, the FDA classified the drugs as adulterated and unsafe. Although the company submitted an initial response in April 2026, the FDA determined it was insufficient due to a lack of supporting documentation, such as employee training records and updated treatment logs. The FDA requires DeJong Family Dairy to provide a written response within 15 working days detailing the corrective actions taken to ensure future compliance. This response must include evidence of staff training and improved record-keeping practices to prevent the recurrence of these violations. Failure to address these concerns promptly may result in further regulatory or legal action.